Betmiga

PreclinicalSmall molecule

Astellas

Betmiga is one of 24 small molecule programs targeting Overactive Bladder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Overactive BladderActive, not recruiting

Overactive BladderPreclinical

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Overactive Bladder

#DrugCompanyPhaseTrials

Myrbetriq

Astellas

Approved

45 2

Vesicare

Astellas

Approved

47 3

Enablex

AbbVie

Approved

8 4

Detrol La

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

21 5

Toviaz

Pfizer

Approved

16 6

Flomax

Sanofi

Approved

2 7

Cialis

Eli Lilly

Approved

2 8

Oxytrol

WWim Janssens

Approved

9 9

Levitra

Bayer

Approved

—10

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Overactive Bladder1 trial

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice

Completed· Astellas logo

Astellas··NCT02320773·863 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Betmiga. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Betmiga compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Betmiga. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Astellas

Betmiga

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Overactive Bladder1 trial

References

Drug Info

Quick Facts

Related News